With the approval date for Bristol Myers Squibb’s (BMS) schizophrenia drug KarXT (xanomeline-trospium) looming, prodrugs – medications that start as inactive or less active, and once inside the body, are converted into the active form – have entered the spotlight as Terran Biosciences works on the development of two prodrug versions of KarXT.
This month’s cover story looks at the virtues of prodrugs in avoiding adherence issues and Terran’s use of the US Food and Drug Administration’s (FDA) unique 505(b)(2) pathway to bring its prodrug versions of KarXT to market more quickly.
Also, this month, we look at whether pharmacy benefit managers (PBMs) are to blame for high drug prices in the US, developing vaccines for Disease X, and a comment piece reflects on the Biden administration’s price cut announcements negotiated by the Centers for Medicare and Medicaid Services (CMS) for the first ten selected drugs under the Inflation Reduction Act.
Read the latest issue of Pharma Technology Focus for all this and insights, and analysis from the pharmaceutical industry.
You can also subscribe here to receive email notifications when a new issue is available.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
